Biophytis to test BIO101 for limiting weight regain in OBA obesity trial

• Biophytis outlined plans to evaluate BIO101 in the OBA obesity study, targeting weight regain following weight loss.
• No clinical results were presented; readouts are expected in the future as the trial progresses.
• The study aims to show whether BIO101 can help patients better maintain weight loss, supporting a potential obesity positioning for the drug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.